Dear AEK and other ihub participants,
Shortly after the stock manipulation on May 10, I too wrote to StatNews, complaining about Feuerstein. I decided then not to post it on this board, but now I want to support you, AEK, and I hope many others, in their communications with the owners and editorial staff of StatNews. I sent my email only to the general reply address of StatNews, not to the Henrys. The Globe has a reputation for integrity (e.g., its investigation of child molestation by members of the Massachusetts clergy) and one may hope that the owners will pay attention to our exposures of deliberate lying by one of their reporting staff. Thus, I hope we will be joined by many others scientists, physicians, investors, and patients, who are outraged by the promulgation of these lies.
In any case, here is the content of what I sent to StatNews. Please note that I borrowed freely from other contributors in presenting some of the salient data. I didn't feel that attributions were called for in this context.
---------------------------------------------
Are we supposed to believe the stories carried by StatNews when your “journalist”, Adam Feurerstein, the self-described “Night King of biotech” (whatever that means other than pure ego), deliberately displays a false interpretation of a single sentence that he has taken out of context from the Northwest Biotherapeutics presentation yesterday?
He referred to a statement that compared progression-free survival (PFS) for control vs. treated patients. It showed slightly worse results for the treatment, but the explanation is well-understood for all of the new generation of cancer drugs where it is difficult to distinguish between the symptoms of the actual disease and the symptoms of an immune reaction to the drug itself. The former can kill the patient, the latter disappears with careful monitoring and is a natural part of the treatment response in some cases. For that very reason, Northwest chose to NOT use PFS as an endpoint for its phase 3 trial. Nevertheless, Feuerstein ignored that and instead misrepresented the statement to insist that the entire trial had failed. He is either remarkably ignorant or else something even more malignant is present in terms of personal gain at the expense of cancer victims.
The real facts are that the trial met its primary goals for both newly-diagnosed and recurrent glioblastoma and blew away the results of previous trials over the past 20 to 30 years. In addition, compared to existing treatments, NWBO’s DCVAX-L for NEWLY diagnosed GBM provided an overall survival tail that had not been seen before:
30% MORE patients on DCVAX-L lived for up to 36 months
59% MORE patients on DCVAX-L lived for up to 48 months
128% MORE patients on DCVAX-L lived for up to 60 months
(E.g., one expects that more than twice as many patients will live up to 5 years after DCVAX-L treatment than has heretofore been expected).
Compared to existing treatments, NWBO’s DCVAX-L for Recurrent GBM outcomes were:
42% MORE patients on DCVAX-L lived for up to 6 months
75% MORE patients on DCVAX-L lived for up to 12 months
100% MORE patients on DCVAX-L lived for up to18 months
115% MORE patients on DCVAX-L for lived up to 24 months
117% MORE patients on DCVAX-L lived for up to 30 months
So my questions to StatNews are a) Why aren’t you covering this big story? and b) Why is this guy working for you?
News 
Market Data 
Discover 
